1. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting.
- Author
-
Monsalve Y, Tosi G, Ruozi B, Belletti D, Vilella A, Zoli M, Vandelli MA, Forni F, López BL, and Sierra L
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal chemistry, Blood-Brain Barrier drug effects, Brain drug effects, Chitosan adverse effects, Humans, Mice, Nanoparticles adverse effects, Polyethylene Glycols administration & dosage, Polyethylene Glycols adverse effects, Central Nervous System drug effects, Chitosan administration & dosage, Drug Delivery Systems, Nanoparticles administration & dosage
- Abstract
Aim: Drug targeting to the CNS is challenging due to the presence of blood-brain barrier. We investigated chitosan (Cs) nanoparticles (NPs) as drug transporter system across the blood-brain barrier, based on mAb OX26 modified Cs., Materials & Methods: Cs NPs functionalized with PEG, modified and unmodified with OX26 (Cs-PEG-OX26) were prepared and chemico-physically characterized. These NPs were administered (intraperitoneal) in mice to define their ability to reach the brain., Results: Brain uptake of OX26-conjugated NPs is much higher than of unmodified NPs, because: long-circulating abilities (conferred by PEG), interaction between cationic Cs and brain endothelium negative charges and OX26 TfR receptor affinity., Conclusion: Cs-PEG-OX26 NPs are promising drug delivery system to the CNS.
- Published
- 2015
- Full Text
- View/download PDF